Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery

Journal of Clinical Oncology

Volumn 19, Issue 11, 2001, Pages 2821-2828

  Kushner, B H ^a   Wolden, S ^a   LaQuaglia, M P ^a   Kramer, K ^a   Verbel, D ^a   Heller, G ^a   Cheung, N K V ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; MONOCLONAL ANTIBODY; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CHILD; CORRELATION FUNCTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NEUROBLASTOMA; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; TREATMENT FAILURE;

EID: 0035366395     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.11.2821     Document Type: Article

References (54)

1. Impact of intensified therapy on clinical outcome in infants and children with neuroblastoma: The St. Jude Children's Research Hospital experience, 1962 to 1988
2. Escalating dose of continuous infusion combination chemotherapy for refractory neuroblastoma
3. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age
4. NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: A report from the French Society of Pediatric Oncology
5. Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: A report of two concurrent Children's Cancer Group studies
6. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid
7. D2 antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age
8. High-dose chemoradiotherapy supported by marrow infusions for advanced neuroblastoma: A Pediatric Oncology Group study
9. Myeloablative therapy and unpurged autologous bone marrow transplantation for poor-prognosis neuroblastoma: Report of 34 cases
10. Therapeutic significance of surgery in advanced stage neuroblastoma: A report from the Study Group of Japan
11. Sites of relapse in patients with neuroblastoma following bone marrow transplantation in relation to preparatory "debulking" treatments
12. Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: A Childrens Cancer Group pilot study
13. Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: A report from the Childrens Cancer Group
14. Patterns of failure following total body irradiation and bone marrow transplantation with or without a radiotherapy boost for advanced neuroblastoma
15. A study of thiotepa, etoposide and fractionated total body irradiation as preparative regimen prior to bone marrow transplantation for poor prognosis patients with neuroblastoma
16. Myeloablative therapy and bone marrow rescue in advanced neuroblastoma: Report from the Italian Bone Marrow Transplant Registry
17. Thiotepa and cyclophosphamide with stem cell rescue for consolidation therapy for children with high-risk neuroblastoma: A phase I/II study of the Pediatric Blood and Marrow Transplant Consortium
18. Aggressive surgery combined with intensive chemotherapy improves survival in poor-risk neuroblastoma
19. Stage 4 neuroblastoma diagnosed at more than 1 year of age: Gross total resection and clinical outcome
20. The changing role of radiation therapy in the treatment of neuroblastoma
21. Neuroblastoma: Biology and therapy
22. Dose response analysis of pediatric neuroblastoma to megavoltage radiation
23. Radiation therapy in the management of neuroblastoma: The Duke University Medical Center experience 1967-1984
24. Pediatric neuroblastoma: Postoperative radiation therapy using less than 2000 rad
25. Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy
26. Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy
27. Successful management of low-stage neuroblastoma without adjuvant therapies: A comparison of two decades, 1972 through 1981 and 1982 through 1992, in a single institution
28. Radiotherapy improves the outlook for patients older than 1 year with Pediatric Oncology Group stage C neuroblastoma
29. N-myc amplification is a major prognostic factor in localized neuroblastoma: Results of the French NBL 90 Study
30. Serum lactate dehydrogenase in childhood neuroblastoma: A Pediatric Oncology Group recursive partitioning study
31. Intra-operative radiation therapy in pediatric neuroblastoma
32. Intraoperative radiation therapy for high risk pediatric neuroblastoma
33. Local control with multi-modality therapy for stage 4 neuroblastoma
34. Myeloablative combination chemotherapy without total body irradiation for neuroblastoma
35. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment
36. Coordinated use of sequentially escalated cyclophosphamide and cell-cycle-specific chemotherapy (N4SE protocol) for advanced neuroblastoma: Experience with 100 patients
37. Dose-intensive use of cyclophosphamide in ablation of neuroblastoma
38. N7: A novel multi-modality therapy of high risk neuroblastoma (NB) in children over 1 year of age
39. The analysis of failure time data in the presence of competing risks
40. Nonparametric estimation from incomplete observations
41. Treatment of advanced neuroblastoma with supralethal chemotherapy, radiation, and allogeneic or autologous marrow reconstitution
42. Neuroblastoma: The Joint Center for Radiation Therapy/Dana-Farber Cancer Institute/Children's Hospital experience
43. Advanced neuroblastoma: Improved response rate using a multiagent regimen (OPEC) including sequential cisplatin and VM-26
44. The radiobiology of human neuroblastoma
45. Radiobiological considerations in the treatment of neuroblastoma by total body irradiation
46. Changes in early and late radiation responses with altered fractionation: Implications for dose-survival relationships
47. Radiation induced height impairment in pediatric Hodgkin's disease
48. An update of pediatric radiation oncology
49. 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma
50. 131I-metaiodobenzylguanidine in the treatment of neuroblastoma
51. 131I-metaiodobenzylguanidine therapy in neuroblastoma spheroids of different sizes
52. 125I]iodobenzylguanidine on neuroblastoma multicellular tumor spheroids of different sizes
53. Oral etoposide for refractory and relapsed neuroblastoma
54. Neuroblastoma metastatic to the central nervous system: The Memorial Sloan-Kettering Cancer Center experience and a literature review